Category Archives: R&D

Drug-Diagnostic Development Stymied by Payer Concerns

The shift to personalized medicine, which supports medical treatment tailored to individual patient characteristics, has been hindered by uncertainty over the value, accuracy and clinical utility of companion diagnostic tests. Even for the handful of drugs approved by the Food and Drug Administration with labeling that links prescribing to specific biomarker measures, health plan operators, […]
Also posted in FDA, Gene therapy, Legal, Market Access, Regulatory, Technology | Tagged , , , , , , , , , | Leave a comment

Casing Cancer: ASCO Launches New Series on State of the Disease

Despite its importance as a vital indicator of overall population health status, cancer suffers from an information deficit – particularly when considered from a global perspective. The American Society of Clinical Oncology [ASCO], the lead professional group in this space, is now working to rectify at least part of the gap with the launch of […]
Also posted in healthcare, leadership, Market Access, pricing, Regulatory, Safety, Strategy | Tagged , , , , , | Leave a comment

Drug Discovery CRO Sector to Thrive in Europe

The European pharmaceutical industry is changing its approach to R&D and is increasingly relying on outsourcing for drug discovery, writes Faiz Kermani. The European pharmaceutical industry accounts for nearly 40% of the global industry’s R&D investment. Although  companies are responding to current pressures by closing R&D sites, they still need to support their ongoing drug-development projects […]
Also posted in Europe, Events, Global, Guest Blog | Tagged , , , | Leave a comment

Obama Budget Takes Slap at Pharma

Despite a slight boost in funding for the Food and Drug Administration and stronger tax incentives for investment in R&D, significant changes in Medicare drug reimbursement and coverage policies have biopharmaceutical companies up in arms.
Also posted in Biotech, IP, Legal, Regulatory | Tagged , , , | Leave a comment

Venn Life Sciences Puts LabSkin in the Game

Just think what Frankenstein could do with this product. It looks like skin, feels like skin, but it’s not skin. It’s LabSkin, a facsimile, being manufactured by a clinical research group Venn Life Sciences. Demand for replacement technologies stemmed from the European Union ban on selling cosmetics tested on animals in March 2013, proving where […]
Also posted in Deals, Technology | Tagged , , , | Leave a comment
  • Categories

  • Meta